Please assess the completion status of the following clinical trial:

Trial Title: PTG-300 in Subjects With Hereditary Hemochromatosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged 18 and older~* Confirmed diagnosis of HFE-related hereditary hemochromatosis with prior genotype testing~* Documented stable phlebotomy for ≥ 6 months~* Screening hemoglobin \>11.5 g/dL~* Documented evidence of prior serum ferritin ≥500 ng/mL~* Serum ferritin \>50 ng/mL and \<300 ng/mL at screening~Exclusion Criteria:~* Clinically meaningful laboratory abnormality~* Receiving iron chelation therapy~* Receiving erythrocytapheresis~* Pregnant or lactating females~* Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infections requiring antimicrobial therapy within 4 weeks of dosing.~* Serious or unstable medical or psychiatric condition that would prevent subject providing informed consent~* Organ damage from iron overload~* Primary or secondary immunodeficiency~* Positive hepatitis B or hepatitis C or known human immunodeficiency virus infection~* Known history of autoimmune/inflammatory diseases~* Any surgical procedures requiring general anesthesia within 1 month prior to screening or planned surgery during study~* History of invasive malignancies within last 2 years, except non-malignant skin cancer and local cured prostate cancer, cervical cancer, or ductal carcinoma in situ~* Receipt of an investigational agent within 30 days of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTG-300 (Type: EXPERIMENTAL): PTG-300 Subcutaneous

Based on this trial design, predict the completion outcome and termination type (if applicable).